Silo Pharma (NASDAQ:SILO) Posts Quarterly Earnings Results

Silo Pharma (NASDAQ:SILO) issued its quarterly earnings data on Friday. The company reported ($0.21) earnings per share (EPS) for the quarter, Zacks reports. Silo Pharma had a negative return on equity of 81.75% and a negative net margin of 6,726.39%.

Silo Pharma Stock Down 3.7%

NASDAQ:SILO traded down $0.07 during trading hours on Friday, reaching $1.84. 48,855 shares of the company’s stock were exchanged, compared to its average volume of 168,715. The firm has a market capitalization of $2.93 million, a price-to-earnings ratio of -0.42 and a beta of 0.81. The company has a 50-day moving average of $1.57 and a 200 day moving average of $4.37. Silo Pharma has a 1-year low of $1.10 and a 1-year high of $10.43.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Silo Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One analyst has rated the stock with a Sell rating. According to MarketBeat, the company presently has a consensus rating of “Sell”.

Silo Pharma Company Profile

Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on developing therapeutics that combine traditional pharmaceutical approaches with psychedelic research. The company’s programs are intended to address conditions involving pain, inflammation, neurological disorders, and mental health. Silo Pharma’s pipeline has included SP-26, an investigational ketamine-based implant designed to provide sustained drug delivery and being explored for conditions such as fibromyalgia. Its research portfolio has also included intranasal formulations and other therapeutics targeting disorders such as post-traumatic stress disorder and Alzheimer’s disease.